Skip to main content
Journal cover image

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

Publication ,  Journal Article
Bilder, RM; Goldman, RS; Volavka, J; Czobor, P; Hoptman, M; Sheitman, B; Lindenmayer, JP; Citrome, L; McEvoy, J; Kunz, M; Chakos, M ...
Published in: American Journal of Psychiatry
2002

Objective: Newer antipsychotic drugs have shown promise in ameliorating neurocognitive deficits in patients with schizophrenia, but few studies have compared newer antipsychotic drugs with both clozapine and conventional agents, particularly in patients who have had suboptimal response to prior treatments. Method: The authors examined the effects of clozapine, olanzapine, risperidone, and haloperidol on 16 measures of neurocognitive functioning in a double-blind, 14-week trial involving 101 patients. A global score was computed along with scores in four neurocognitive domains: memory, attention, motor function, and general executive and perceptual organization. Results: Global neurocognitive function improved with olanzapine and risperidone treatment, and these improvements were superior to those seen with haloperidol. Patients treated with olanzapine exhibited improvement in the general and attention domains but not more than that observed with other treatments. Patients treated with risperidone exhibited improvement in memory that was superior to that of both clozapine and haloperidol. Clozapine yielded improvement in motor function but not more than in other groups. Average effect sizes for change were in the small to medium range. More than half of the patients treated with olanzapine and risperidone experienced "clinically significant" improvement (changes in score of at least one-half standard deviation relative to baseline). These findings did not appear to be mediated by changes in symptoms, side effects, or blood levels of medications. Conclusions: Patients with a history of suboptimal response to conventional treatments may show cognitive benefits from newer antipsychotic drugs, and there may be differences between atypical antipsychotic drugs in their patterns of cognitive effects.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

American Journal of Psychiatry

DOI

ISSN

0002-953X

Publication Date

2002

Volume

159

Issue

6

Start / End Page

1018 / 1028

Related Subject Headings

  • Psychiatry
  • 5203 Clinical and health psychology
  • 3202 Clinical sciences
  • 17 Psychology and Cognitive Sciences
  • 11 Medical and Health Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bilder, R. M., Goldman, R. S., Volavka, J., Czobor, P., Hoptman, M., Sheitman, B., … Lieberman, J. A. (2002). Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. American Journal of Psychiatry, 159(6), 1018–1028. https://doi.org/10.1176/appi.ajp.159.6.1018
Bilder, R. M., R. S. Goldman, J. Volavka, P. Czobor, M. Hoptman, B. Sheitman, J. P. Lindenmayer, et al. “Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.” American Journal of Psychiatry 159, no. 6 (2002): 1018–28. https://doi.org/10.1176/appi.ajp.159.6.1018.
Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. American Journal of Psychiatry. 2002;159(6):1018–28.
Bilder, R. M., et al. “Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.” American Journal of Psychiatry, vol. 159, no. 6, 2002, pp. 1018–28. Scival, doi:10.1176/appi.ajp.159.6.1018.
Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper TB, Horowitz TL, Lieberman JA. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. American Journal of Psychiatry. 2002;159(6):1018–1028.
Journal cover image

Published In

American Journal of Psychiatry

DOI

ISSN

0002-953X

Publication Date

2002

Volume

159

Issue

6

Start / End Page

1018 / 1028

Related Subject Headings

  • Psychiatry
  • 5203 Clinical and health psychology
  • 3202 Clinical sciences
  • 17 Psychology and Cognitive Sciences
  • 11 Medical and Health Sciences